Research programme: bacteriophage therapies - Pherecydes

Drug Profile

Research programme: bacteriophage therapies - Pherecydes

Alternative Names: P. aeruginosa phage therapy - Pherecydes; PP 1231; PP 2351; S. aureus phage therapy - Pherecydes

Latest Information Update: 31 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pherecydes Pharma
  • Class Bacteriophages; Pseudomonas phages; Staphylococcus phages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bone and joint infections; Respiratory tract infections

Most Recent Events

  • 29 Aug 2016 Pherecydes Pharma plans phase I/II trials for Bone and joint infections and Respiratory tract infections (Pherecydes pipeline, August 2016)
  • 29 Aug 2016 Preclinical trials in Bone and joint infections in France (unspecified route) (Pherecydes Pharma pipeline, August 2016)
  • 29 Aug 2016 Preclinical trials in Respiratory tract infections in France (Inhalation) (Pherecydes Pharma pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top